Brightman B K, Rein A, Trepp D J, Fan H
Department of Molecular Biology and Biochemistry, University of California, Irvine 92717.
Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2264-8. doi: 10.1073/pnas.88.6.2264.
Moloney murine leukemia virus (Mo-MuLV) induces T-cell lymphoma when inoculated into neonatal mice. This is a multistep process. Early events observed in infected mice include generalized hematopoietic hyperplasia in the spleen and appearance of mink cell focus-inducing (MCF) recombinants; end-stage tumors are characterized by insertional proviral activation of protooncogenes. We previously showed that an Mo-MuLV enhancer variant, Mo+PyF101 Mo-MuLV, has greatly reduced leukemogenicity and is deficient in induction of preleukemic hyperplasia. In this report, we have examined Mo+PyF101 Mo-MuLV-inoculated mice for the presence of MCF recombinants. In contrast to wild-type Mo-MuLV-inoculated mice, Mo+PyF101 Mo-MuLV-inoculated mice did not generate detectable MCF recombinants. This failure was at least partly due to an inability of the MCF virus to propagate in vivo, since a molecularly cloned infectious Mo+PyF101 MCF virus did not replicate, even when inoculated as a Mo+PyF101 Mo-MuLV pseudotype. These results show that the leukemogenic defect of Mo+PyF101 Mo-MuLV is associated with its inability to generate MCF recombinants capable of replication in vivo. This, in turn, is consistent with the view that MCF recombinants play a significant role in Mo-MuLV-induced disease and, in particular, may play a role early in the disease process.
莫洛尼鼠白血病病毒(Mo-MuLV)接种到新生小鼠体内会诱发T细胞淋巴瘤。这是一个多步骤过程。在受感染小鼠中观察到的早期事件包括脾脏中全身性造血组织增生以及貂细胞集落诱导(MCF)重组体的出现;终末期肿瘤的特征是原癌基因的插入性前病毒激活。我们之前表明,一种Mo-MuLV增强子变体Mo+PyF101 Mo-MuLV的致白血病性大大降低,并且在诱导白血病前期增生方面存在缺陷。在本报告中,我们检查了接种Mo+PyF101 Mo-MuLV的小鼠中是否存在MCF重组体。与接种野生型Mo-MuLV的小鼠不同,接种Mo+PyF101 Mo-MuLV的小鼠未产生可检测到的MCF重组体。这种失败至少部分是由于MCF病毒无法在体内繁殖,因为分子克隆的感染性Mo+PyF101 MCF病毒即使作为Mo+PyF101 Mo-MuLV假型接种也不会复制。这些结果表明,Mo+PyF101 Mo-MuLV的致白血病缺陷与其无法产生能够在体内复制的MCF重组体有关。反过来,这与MCF重组体在Mo-MuLV诱导的疾病中起重要作用的观点一致,特别是可能在疾病过程的早期起作用。